Secondary hypogonadism: where low testosterone actually starts.

“Low testosterone” names a number. It doesn’t name a cause. The clinical term for the condition is hypogonadism— the testicles aren’t producing what a man’s body needs — and the far more useful question, the one that decides what happens next, is where in the system the breakdown sits.

There are two places it can sit, and they behave completely differently. In primary hypogonadism, the testicles themselves can’t do the job even though the instruction to do it is arriving loud and clear. In secondary hypogonadism, the testicles are perfectly capable — the instruction never shows up. Same low number on the lab slip. Two different problems. This is a plain-English walk through how that system works, how the two are told apart, and why a single testosterone value read on its own can be genuinely misleading.

The short answer, up front

Secondary hypogonadism is a signal problem.The hypothalamus and the pituitary gland — the two structures at the base of the brain that run the male hormonal system — aren’t sending enough of the instruction that tells the testicles to produce testosterone. The factory works. The order never came through. It is also called hypogonadotropic hypogonadism, after the gonadotropin hormones that carry the instruction.

Primary hypogonadism is a production problem.The instruction arrives, and arrives insistently, but the testicles can’t answer it. And in real practice a great many men present with a mixed picture— some signal loss on top of some production loss, usually accumulated over years. Mixed is common. It’s not a technicality.

The chain of command: how testosterone is actually ordered

Testosterone isn’t produced on a whim. It runs on a chain of command that endocrinology calls the hypothalamic-pituitary-testicular axis — the HPTA. It works like this:

• The hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses. This is the opening instruction.
• GnRH tells the pituitary gland to release two messenger hormones into the bloodstream: LH (luteinizing hormone) and FSH (follicle-stimulating hormone).
• LH travels to the testicles and instructs the Leydig cells to produce testosterone. FSH instructs the Sertoli cells, which support sperm production.
• Circulating testosterone then reports back to the hypothalamus and pituitary, which throttle the signal down. Levels fall, the throttle opens again. It’s a thermostat, not a switch.

That feedback loop is the whole reason the diagnosis is knowable. When testosterone drops, a healthy pituitary responds— it pushes LH higher, trying to get the message through. So the level of LH in the blood tells you whether the top of the system is doing its job. Testosterone reads the bottom half of the axis. LH reads the top half. You need both halves to know what you’re looking at.

Why LH sits on the basic panel

This is the practical payoff, and it’s the reason luteinizing hormone appears on the evaluation panel at Castellano Health Institute rather than being reserved for a specialist referral later. One extra tube answers the question that changes the whole workup.

Notice the middle row, because it’s the one that gets missed most easily. An LH result in the middle of the reference range looks unremarkable on paper. But in a man whose testosterone is genuinely low, a mid-range LH is the wrong answer — the pituitary is supposed to be shouting by then. Reading LH as a number against a range, instead of as a response to the testosterone next to it, is how a secondary picture gets read as nothing at all. The whole panel is described in detail on the TRT lab panel page.

What actually causes each one

The cause lists look intimidating written out, but the honest summary is short: the rare causes are dramatic and the common causes are ordinary.

Read the right-hand column again. Klinefelter syndrome and pituitary tumors are real and they do get found — but the entries that account for most secondary hypogonadism in a general men’s health practice are excess body fat, untreated sleep apnea, and chronic illness. Fat tissue is metabolically active: it converts testosterone to estrogen and produces inflammatory signals that suppress the hypothalamus. Poor sleep blunts the overnight pulse pattern the whole axis depends on. Neither of those is exotic, and both are extremely common in men in their forties and fifties.

That’s also why the classification isn’t academic. When something identifiable is suppressing the signal, that finding belongs in the plan — not filed away as a separate project for some other day. Dr. Castellano works the hormonal picture and the underlying metabolic picture as one case, in one practice, because in most men they are one case.

Total, free, and bioavailable — why one number isn’t the whole story

There’s a second reason a testosterone result can be read too quickly, and it has nothing to do with the HPTA axis. It has to do with how testosterone travels.

Once testosterone enters the bloodstream, most of it is immediately bound to carrier proteins and taken out of circulation. Roughly 45% is bound tightly to a protein called sex hormone-binding globulin (SHBG). Roughly 50% is bound loosely to albumin. Only about 2%floats free. And here’s the part that matters: only free testosterone can bind the androgen receptor and do anything at all. The loosely-albumin-bound fraction can release easily enough to count as usable, which is why clinicians talk about two derived figures:

• Total testosterone = free + albumin-bound + SHBG-bound. Everything in the tube.
• Bioavailable testosterone = free + albumin-bound. The portion actually available to your tissues.

SHBG isn’t a constant. It rises with age, and it rises with a long list of chronic conditions. When SHBG climbs, it locks up more of the testosterone in the tube. The total can come back looking perfectly respectable while the bioavailable fraction — the part your muscle, brain, and bone can use — has quietly fallen. That is the mechanism behind an experience a lot of men describe: real symptoms, and a lab result that looked fine.

This is not an argument for ordering every hormone assay that exists. It’s an argument for reading the panel against the man in front of you. The basic evaluation at Castellano Health Institute is kept deliberately lean — total testosterone, estradiol, LH, a complete blood count, and PSA when age calls for it — and further testing is added when the clinical picture calls for it, not by default. What makes that work isn’t the length of the panel. It’s that the same physician reads the labs alongside your history and your symptoms, every visit, against your own baseline.

How the diagnosis is actually made

A hypogonadism diagnosis is symptoms plus labs— never one without the other. The labs are not a single draw either. Testosterone swings across the day and from day to day, peaking in the morning, so the standard is low levels confirmed on two separate mornings. American Urological Association guidance uses a total testosterone at or below 300 ng/dL, measured on two early-morning samples, as the threshold for a low-testosterone diagnosis.

The daily swing is worth knowing about, because it explains a lot of confusing results. In younger men the drop from morning to afternoon can run 20–25%. An afternoon draw in a man with a genuine deficiency can land well below where his true morning level sits — and in an older man, whose daily variation is considerably flatter, the same afternoon draw means something different again. Timing is not a formality.

Symptoms don’t all arrive at the same level

One of the most useful findings in this literature is that low-testosterone symptoms don’t switch on together at one magic cutoff. They accumulate as levels fall, in a fairly consistent order. A 2006 study published in the Journal of Clinical Endocrinology & Metabolism examined 434 men aged 50 to 86 and found no clean single threshold for late-onset hypogonadism at all — instead, specific complaints became significantly more common below specific levels.

Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men.J Clin Endocrinol Metab. 2006;91(11):4335–43. PMID 16926258. Cross-sectional cohort of 434 andrology outpatients; the authors also identified erectile dysfunction as a composite of metabolic risk, smoking and depressive symptoms rather than a testosterone finding alone.

Read that ladder from the top down and the clinical point becomes obvious. Libido and drive start to go at a level well above any commonly quoted cutoff. Erectile dysfunction — the symptom most men think of as thelow-testosterone symptom — shows up near the bottom, after the level has fallen a long way. Waiting for the last symptom on the list before taking the first one seriously is backwards. The fuller symptom picture is walked through in this piece on low testosterone in men over 40.

That’s the book making the point with the volume up. The clinical version is quieter and says the same thing: the adult male reference range is very wide, it was built to describe a population rather than to predict how any one man feels, and a result inside it is a starting point for the conversation rather than the end of it. That is exactly why symptoms are half the diagnosis.

One more wrinkle: the reference range itself has been moving

There’s a finding that complicates the idea of a fixed “normal.” A prospective cohort study published in the same journal in 2007 followed randomly selected men aged 45 to 79 in greater Boston across three collection waves — from the late 1980s through the early 2000s — producing 2,769 observations on 1,532 men. The researchers found a substantial age-independent decline in testosterone across calendar time: a 60-year-old measured in the later waves had a meaningfully lower average level than a 60-year-old measured in the first. The decline was notexplained by observed changes in the men’s health and lifestyle characteristics, including smoking and obesity, and it was larger than the decline normally attributed to aging itself.

Travison TG, Araujo AB, O’Donnell AB, Kupelian V, McKinlay JB. A population-level decline in serum testosterone levels in American men.J Clin Endocrinol Metab. 2007;92(1):196–202. PMID 17062768.

The practical takeaway isn’t alarm. It’s that a reference range describes the population that was measured, and that population has been changing. Which brings the answer back to the same place every time: your symptoms, your labs, drawn correctly, read together, by a physician who knows what your own numbers did last time.

What happens once you know which one it is

Naming the type doesn’t change what testosterone replacement therapy is. It changes what else belongs in the plan and what conversation you should be having. A man with a clear secondary picture and untreated sleep apnea is a different case from a man with primary testicular failure after chemotherapy, even if their testosterone results are identical. The first man has a driver worth working. The second man’s testicles are not going to be talked back into production.

Fertility is part of that conversation too. Testosterone replacement suppresses the body’s own signal through the same feedback loop described above, which reduces sperm production — so if you are planning to father children, that needs to be on the table before therapy starts, not discovered afterward. It’s a standard part of the first visit here.

And whichever type you have, the therapy is not the whole answer by itself. As Dr. Castellano describes it in his book: testosterone is like gasoline — you can pour it over a pile of wood, but without a match all you have is wet wood. Exercise is the match. Replacement makes the change possible; the work is what turns possible into results. If you want the realistic sequence of what happens when, there’s a month-by-month timeline here.

From there it’s read, not assumed. Bloodwork is rechecked at 8 weeks — the point where levels have stabilized enough to judge whether the dose is right — and tracked from there by the same physician, against your own baseline rather than a chart.

Secondary hypogonadism — quick answers